> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Altimmune Ties Alcohol-Trial Timing To Funding That Would Avoid Issuing More Shares
- URL: https://www.bullished.co/altimmune-ties-alcohol-trial-timing-to-funding-that-would-avoid-issuing-more-shares-29322bea/
- Published: 2026-11-12T14:46:08.000Z
- Updated: 2026-11-12T14:46:08.000Z
- Description: A December FDA meeting will help define the proposed program, while existing resources are expected to cover the MASH readout in 2029.
- Author: Matteo Parrino
- Tags: Earnings, ALT, Industry: Healthcare

[Altimmune](https://www.bullished.co/tag/alt/), which develops treatments for serious liver diseases, tied its proposed late-stage alcohol-use-disorder trial’s timing to regulatory feedback and financing on Thursday’s earnings call. Chief Executive Officer Jerry Durso said the company would first use its [December FDA meeting](https://www.sec.gov/Archives/edgar/data/0001326190/000132619026000067/alt-ex99d1.htm?ref=bullished.co) to help define the study before settling on funding.

## Funding Before A Start Date

“Our preference remains to pursue non-dilutive funding for the program,” Chief Financial Officer Greg Weaver said on the call. The options include royalty debt or a strategic partnership—ways to finance development without issuing additional shares.

Asked by a B. Riley analyst whether the trial could begin in the first half of next year, Durso stressed both speed and financing that serves the program and shareholders. “We're not at a point where we're going to guide specifically on timing,” he said.

Altimmune ended September with [$480 million](https://www.sec.gov/Archives/edgar/data/0001326190/000132619026000067/alt-ex99d1.htm?ref=bullished.co) in cash, cash equivalents and investments, according to its Thursday results release. Weaver expects existing resources to support operations through the anticipated 2029 readout from its late-stage trial in metabolic dysfunction-associated steatohepatitis, or MASH, a metabolic liver disease. Regulatory discussions should clarify the alcohol program’s size and cost, he said.

## Testing Drinking And Liver Benefits

Pemvidutide, Altimmune’s investigational weekly injection, activates glucagon and GLP-1 receptors. The company has no products approved for sale and is testing the drug across MASH, alcohol use disorder and alcohol-associated liver disease.

The company announced alcohol-study results in July. Weekly heavy-drinking days fell by [4.20 days](https://finance.yahoo.com/healthcare/articles/altimmune-presents-positive-breaking-pemvidutide-173000485.html?ref=bullished.co) with pemvidutide, compared with 2.75 days for placebo; participants also received behavioral intervention.

Chief Medical Officer Christophe Arbet-Engels said on the call that the proposed pivotal study would target moderate to severe alcohol use disorder, including patients with advanced liver impairment. Management proposes testing 1.8-milligram and 2.4-milligram doses, with gradual dose increases.

The proposed main measure would assess drinking-risk levels, with freedom from heavy-drinking days as a key secondary measure. Drinking benefits would be assessed at 26 weeks, with follow-up extending to one year for additional safety and efficacy data. The final design remains subject to regulatory discussions.

## Liver Trials Raise Development Spending

Altimmune began its late-stage MASH trial in July. Its mid-stage alcohol-associated liver disease study has completed enrollment, with results expected in the second half of 2027.

Third-quarter [research spending rose](https://www.globenewswire.com/news-release/2026/11/12/3401460/0/en/altimmune-announces-third-quarter-2026-financial-results-and-business-update.html?ref=bullished.co) to $27.0 million from $15.0 million a year earlier. The company attributed the increase primarily to those MASH and alcohol-associated liver disease trials; $20.3 million went toward direct pemvidutide development costs.

Administrative expenses increased to $8.7 million from $5.9 million, primarily because of compensation and professional services, the company said. Its net loss widened to $31.6 million from $19.0 million, while the per-share loss was $0.15 versus $0.21.

Durso expects to communicate the FDA discussion’s outcome after receiving meeting minutes, which typically arrive within 30 days. Management also anticipates European regulatory dialogue in the first quarter.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Altimmune results release (Form 8-K, EX-99.1)](https://www.sec.gov/Archives/edgar/data/0001326190/000132619026000067/alt-ex99d1.htm?ref=bullished.co) — SEC EDGAR
- [Altimmune gears up for FDA meeting on pivotal Phase 3 trial in alcohol use disorder - BioSpace](https://www.biospace.com/drug-development/altimmune-gears-up-for-fda-meeting-on-pivotal-phase-3-trial-in-alcohol-use-disorder?ref=bullished.co) — biospace.com
- [Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology](https://finance.yahoo.com/healthcare/articles/altimmune-announces-publication-impact-phase-121500695.html?ref=bullished.co) — Yahoo Finance
- [Altimmune's Pemvidutide Meets Primary Endpoint in Phase 2 Alcohol Use Disorder Trial](https://finance.yahoo.com/healthcare/articles/altimmune-apos-pemvidutide-meets-primary-200030550.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder](https://finance.yahoo.com/healthcare/articles/altimmune-presents-positive-breaking-pemvidutide-173000485.html?ref=bullished.co) — Yahoo Finance
- [Altimmune Announces Third Quarter 2026 Financial Results](https://www.globenewswire.com/news-release/2026/11/12/3401460/0/en/altimmune-announces-third-quarter-2026-financial-results-and-business-update.html?ref=bullished.co) — globenewswire.com

### More on Altimmune

- [Altimmune Holds $480 Million To Back Its Experimental Liver-Drug Program](https://www.bullished.co/altimmune-holds-480-million-to-back-its-experimental-liver-drug-program-36697d53/)
- [State Street Holds 4.3% Of Altimmune Without Seeking To Influence Its Control](https://www.bullished.co/state-street-holds-4-3-of-altimmune-without-seeking-to-influence-its-control-334bf901/)
- [Altimmune Draws $10 Million From Hercules Loan, Pushing Interest-Only Period To June 2028](https://www.bullished.co/altimmune-draws-10-million-from-hercules-loan-pushing-interest-only-period-to-june-2028-7500d49d/)

[All Altimmune (ALT) coverage →](https://www.bullished.co/tag/alt/)